Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen.

Dastjerdi MH, Hamrah P, Dana R.

Cornea. 2009 Dec;28(10):1091-6. doi: 10.1097/ICO.0b013e3181a16472.

2.

[A 0,05% cyclosporine treatment of the advanced dry eye syndrome].

Kujawa A, Rózycki R.

Klin Oczna. 2005;107(4-6):280-6. Polish.

PMID:
16118939
3.

Ophthalmic cyclosporine use in ocular GVHD.

Lelli GJ Jr, Musch DC, Gupta A, Farjo QA, Nairus TM, Mian SI.

Cornea. 2006 Jul;25(6):635-8.

PMID:
17077652
4.

Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.

Wilson SE, Perry HD.

Ophthalmology. 2007 Jan;114(1):76-9. Epub 2006 Oct 27.

PMID:
17070588
5.

[Current treatments of xerophthalmia in Sjögren's syndrome].

Baudouin C, Pisella PJ, Brignole F.

Rev Med Interne. 2004 May;25(5):376-82. Review. French.

PMID:
15110955
7.

The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.

Su MY, Perry HD, Barsam A, Perry AR, Donnenfeld ED, Wittpenn JR, D'Aversa G.

Cornea. 2011 Oct;30(10):1098-104. doi: 10.1097/ICO.0b013e318206caee.

PMID:
21407074
8.

Treatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops.

Sanz-Marco E, Udaondo P, García-Delpech S, Vazquez A, Diaz-Llopis M.

J Ocul Pharmacol Ther. 2013 Oct;29(8):776-83. doi: 10.1089/jop.2012.0265. Epub 2013 Aug 15.

9.

Systemic immunomodulatory therapy in severe dry eye secondary to inflammation.

Cordero-Coma M, Anzaar F, Sobrin L, Foster CS.

Ocul Immunol Inflamm. 2007 Mar-Apr;15(2):99-104.

PMID:
17558834
10.

Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.

Toker E, Asfuroğlu E.

Cornea. 2010 Feb;29(2):133-40. doi: 10.1097/ICO.0b013e3181acf68d.

PMID:
19966564
11.

[Cyclosporine eye drops: A 4-year retrospective study (2009-2013)].

Kauss Hornecker M, Charles Weber S, Brandely Piat ML, Darrodes M, Jomaa K, Chast F.

J Fr Ophtalmol. 2015 Oct;38(8):700-8. doi: 10.1016/j.jfo.2015.02.008. Epub 2015 Sep 11. French.

12.

The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome.

Devecı H, Kobak S.

Int Ophthalmol. 2014 Oct;34(5):1043-8. doi: 10.1007/s10792-014-9901-4. Epub 2014 Jan 19.

PMID:
24442759
13.

Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye.

Guzey M, Karaman SK, Satici A, Ozardali I, Sezer S, Bozkurt O.

Clin Exp Ophthalmol. 2009 Aug;37(6):541-9. doi: 10.1111/j.1442-9071.2009.02090.x.

PMID:
19702702
14.

Increased corneal sub-basal nerve density in patients with Sjögren syndrome treated with topical cyclosporine A.

Levy O, Labbé A, Borderie V, Hamiche T, Dupas B, Laroche L, Baudouin C, Bouheraoua N.

Clin Exp Ophthalmol. 2017 Jul;45(5):455-463. doi: 10.1111/ceo.12898. Epub 2017 Jan 21.

PMID:
27957797
15.

Pharmacokinetic evaluation of diquafosol tetrasodium for the treatment of Sjögren's syndrome.

Bremond-Gignac D, Gicquel JJ, Chiambaretta F.

Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):905-13. doi: 10.1517/17425255.2014.915026. Epub 2014 May 6. Review.

PMID:
24797483
16.

Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090.

Contreras-Ruiz L, Mir FA, Turpie B, Krauss AH, Masli S.

Exp Eye Res. 2016 Feb;143:1-8. doi: 10.1016/j.exer.2015.10.008. Epub 2015 Oct 14.

PMID:
26463157
17.

Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.

Rao SN.

J Ocul Pharmacol Ther. 2011 Dec;27(6):603-9. doi: 10.1089/jop.2011.0073. Epub 2011 Oct 14.

PMID:
21999340
18.
19.

Frequent Dosing of Topical Cyclosporine A for Severe Ocular Surface Disease.

Gire AI, Karakus S, Ingrodi SM, Akpek EK.

J Ocul Pharmacol Ther. 2016 Apr;32(3):150-4. doi: 10.1089/jop.2015.0078. Epub 2016 Jan 20.

PMID:
26789928
20.

Topical cyclosporine-A in dry eye associated with chronic graft versus host disease.

Kurt RA, Yalçindag N, Atilla H, Arat M.

Ann Ophthalmol (Skokie). 2009 Fall-Winter;41(3-4):166-9.

PMID:
20214049

Supplemental Content

Support Center